Clostridium difficile infection.

This article reviews the pathogenesis, epidemiology, diagnosis, and treatment of this nosocomial and potentially fatal infectious diarrhea, as well as the associated risk factors. New treatments include fecal microbiota transplantation for disease that is resistant to vancomycin.

[1]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.

[2]  C. Kelly.  Immune response to Clostridium difficile infection. , 1996, European journal of gastroenterology & hepatology.

[3]  A. Price,et al.  CLOSTRIDIUM DIFFICILE AND THE ÆTIOLOGY OF PSEUDOMEMBRANOUS COLITIS , 1978, The Lancet.

[4]  J. Alverdy,et al.  Diverting Loop Ileostomy and Colonic Lavage: An Alternative to Total Abdominal Colectomy for the Treatment of Severe, Complicated Clostridium difficile Associated Disease , 2011, Annals of surgery.

[5]  R. Platt,et al.  Epidemiology of community-acquired Clostridium difficile-associated diarrhea. , 1994, The Journal of infectious diseases.

[6]  C. Pothoulakis.  Pathogenesis of Clostridium difficile-associated diarrhoea. , 1996, European journal of gastroenterology & hepatology.

[7]  T. Louie,et al.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Stockman.  A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile—Associated Diarrhea With High Morbidity and Mortality , 2007 .

[9]  J. Bartlett,et al.  Colitis associated with metronidazole therapy. , 1980, The Journal of infectious diseases.

[10]  J. Silva,et al.  Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. , 1981, The American journal of medicine.

[11]  G. Belle,et al.  Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. , 1989, Gastroenterology.

[12]  L. Morris,et al.  Management of pseudomembranous colitis. , 1994, The American surgeon.

[13]  S. Binion,et al.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate , 1991, Infection and immunity.

[14]  M. Wilcox,et al.  A case-control study of community-associated Clostridium difficile infection. , 2008, The Journal of antimicrobial chemotherapy.

[15]  M. Wilm,et al.  The Enterotoxin from Clostridium difficile (ToxA) Monoglucosylates the Rho Proteins(*) , 1995, The Journal of Biological Chemistry.

[16]  T. Monath,et al.  Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults , 2001, Infection and Immunity.

[17]  D. Gordon,et al.  Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. , 1985, The American journal of gastroenterology.

[18]  D. Leffler,et al.  Treatment of Clostridium difficile-associated disease. , 2009, Gastroenterology.

[19]  J. Meek,et al.  Burden of Clostridium difficile infection in the United States. , 2015, The New England journal of medicine.

[20]  M. Pirmohamed,et al.  Emergence and global spread of epidemic healthcare-associated Clostridium difficile , 2012, Nature Genetics.

[21]  D. Crook,et al.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.

[22]  V. Mai,et al.  Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea , 2013, Journal of Clinical Microbiology.

[23]  L. Bodenstein,et al.  SevereClostridium difficile colitis , 1995, Diseases of the colon and rectum.

[24]  C. Pothoulakis,et al.  Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. , 1992, Gastroenterology.

[25]  S. Calderwood,et al.  Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice , 2007, Infection and Immunity.

[26]  F. Tedesco,et al.  Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. , 1982, Gastroenterology.

[27]  L. Brandt,et al.  The Evolution of Urban C. difficile Infection (CDI): CDI in 2009–2011 Is Less Severe and has Better Outcomes Than CDI in 2006–2008 , 2014, The American Journal of Gastroenterology.

[28]  Esther Jacobowitz Israel,et al.  Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. , 1992, The Journal of clinical investigation.

[29]  M. Keighley,et al.  Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. , 1978, British medical journal.

[30]  C. Bulpitt,et al.  Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial , 2007, BMJ : British Medical Journal.

[31]  J. Stockman.  Treatment with Monoclonal Antibodies against Clostridium difficile Toxins , 2011 .

[32]  P. Bingley,et al.  Clostridium difficile colitis following treatment with metronidazole and vancomycin. , 1987, Postgraduate medical journal.

[33]  C. Surawicz,et al.  Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. , 1990, The Journal of infectious diseases.

[34]  M. Granström,et al.  Serum antibody response to clostridium difficile toxins in patients with clostridium difficile diarrhoea , 1985, Infection.

[35]  Kelly Mills,et al.  Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens , 1994, Journal of clinical microbiology.

[36]  S. Maroo,et al.  Recurrent clostridium difficile. , 2006, Gastroenterology.

[37]  Stuart Johnson,et al.  Effectiveness of Alcohol-Based Hand Rubs for Removal of Clostridium difficile Spores from Hands , 2010, Infection Control & Hospital Epidemiology.

[38]  C. Pothoulakis,et al.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. , 1992, Gastroenterology.

[39]  R. Yolken,et al.  Serum antibody response to toxins A and B of Clostridium difficile. , 1983, The Journal of infectious diseases.

[40]  D. Weaver,et al.  Surgical management of pseudomembranous colitis. , 1988, The American surgeon.

[41]  Melinda B Davis,et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  A. Le Monnier,et al.  Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  F. Barbut,et al.  Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea , 1993, Journal of clinical microbiology.

[44]  S. Miller,et al.  Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[46]  R. Hunt,et al.  Fecal Microbiota Transplantation for Clostridium difficile Infection: Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.

[47]  K. Garey,et al.  Real-Time Polymerase Chain Reaction Detection of Asymptomatic Clostridium difficile Colonization and Rising C. difficile–Associated Disease Rates1 , 2014, Infection Control & Hospital Epidemiology.

[48]  S. Cole,et al.  Hospital-Acquired Clostridium difficile Infections: Estimating All-Cause Mortality and Length of Stay , 2014, Epidemiology.

[49]  L. A. Barroso,et al.  Nucleotide sequence of Clostridium difficile toxin B gene , 1990, Nucleic Acids Res..

[50]  M. Hu,et al.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. , 2009, Gastroenterology.

[51]  L. Miller,et al.  Dose–Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients , 2010, The American Journal of Gastroenterology.

[52]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[53]  A. Zinsmeister,et al.  The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study , 2012, The American Journal of Gastroenterology.

[54]  J. Libby,et al.  Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters , 1982, Infection and immunity.

[55]  W. Silen,et al.  Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. , 1958, Surgery.

[56]  J. Johnson,et al.  Molecular characterization of the Clostridium difficile toxin A gene , 1990, Infection and immunity.

[57]  H. Maarleveld,et al.  Infection control measures to limit the spread of Clostridium difficile. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[58]  J. Bartlett,et al.  Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations , 1981 .

[59]  J. Lamont,et al.  Clostridium difficile colitis , 2004, European Surgery.

[60]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[61]  W. G. Spilg,et al.  Pseudomembranous colitis after treatment with metronidazole. , 1981, British medical journal.

[62]  C. Robertson,et al.  Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum β-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus. , 2013, International journal of antimicrobial agents.

[63]  T. Lamont,et al.  Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. , 2010, Journal of pediatric gastroenterology and nutrition.

[64]  C. Pothoulakis,et al.  Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. , 1991, The Journal of pediatrics.

[65]  D. Crook,et al.  Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection , 2013, Lancet. Infectious Diseases (Print).

[66]  O. Dekkers,et al.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[67]  R Sedivy,et al.  Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. , 1995, The Journal of clinical investigation.

[68]  J. Otter,et al.  The Role Played by Contaminated Surfaces in the Transmission of Nosocomial Pathogens , 2011, Infection Control & Hospital Epidemiology.

[69]  Derrick W. Crook,et al.  Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  Shashank Garg,et al.  Microbiota Dynamics in Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection , 2013, PloS one.

[71]  G. Alangaden,et al.  Intestinal Microbiota Transplantation, a Simple and Effective Treatment for Severe and Refractory Clostridium Difficile Infection , 2014, Digestive Diseases and Sciences.

[72]  C. Kelly,et al.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.

[73]  C. Pothoulakis,et al.  Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins , 1996, Antimicrobial agents and chemotherapy.

[74]  A. Zinsmeister,et al.  Clinical predictors of recurrent Clostridium difficile infection in out‐patients , 2014, Alimentary pharmacology & therapeutics.

[75]  M. Unemo,et al.  Increased Sporulation Rate of Epidemic Clostridium difficile Type 027/NAP1 , 2008, Journal of Clinical Microbiology.

[76]  M. Howell,et al.  Acid Suppression Therapy Does Not Predispose to Clostridium difficile Infection: The Case of the Potential Bias , 2014, PloS one.

[77]  L. Valiquette,et al.  Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec , 2005, Canadian Medical Association Journal.

[78]  C. Pothoulakis,et al.  Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract , 1997, Antimicrobial agents and chemotherapy.

[79]  C. Surawicz,et al.  Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  S. Trottier,et al.  Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  C. Surawicz,et al.  Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics , 1999, Infection Control & Hospital Epidemiology.

[82]  R. Bolton,et al.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. , 1986, Gut.

[83]  L. Valiquette,et al.  Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[84]  Jane W. Marsh,et al.  Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  G. Russell,et al.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. , 2014, JAMA.

[86]  M. Osterman.  Outcomes of Clostridium difficile-Associated Disease Treated With Metronidazole or Vancomycin Before and After the Emergence of NAP1/027 , 2008 .

[87]  M. P. Bauer,et al.  European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[88]  W. Stamm,et al.  Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.

[89]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[90]  J. Silva,et al.  Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. , 1981, The Journal of infectious diseases.

[91]  S. Borriello.  The influence of the normal flora on Clostridium difficile colonisation of the gut. , 1990, Annals of medicine.

[92]  C. Pothoulakis,et al.  Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. , 1993, Gastroenterology.

[93]  P. Kim,et al.  Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters , 1987, Infection and immunity.

[94]  D. Gerding,et al.  PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.

[95]  M. Mann,et al.  Glucosylation of Rho proteins by Clostridium difficile toxin B , 1995, Nature.

[96]  C. Kelly,et al.  Chapter Fifty-One – Treatment of Clostridium difficile diarrhea and colitis , 2006 .

[97]  R. Gilbert,et al.  Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. , 1996, The Journal of clinical investigation.

[98]  R. Barton,et al.  Clindamycin-associated colitis. A prospective study. , 1974, Annals of internal medicine.

[99]  A. Read,et al.  CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHŒA: A ROLE IN INFLAMMATORY BOWEL DISEASE? , 1980, The Lancet.

[100]  I. C. Hall,et al.  INTESTINAL FLORA IN NEW-BORN INFANTS: WITH A DESCRIPTION OF A NEW PATHOGENIC ANAEROBE, BACILLUS DIFFICILIS , 1935 .

[101]  Jon Brazier,et al.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.

[102]  C. Pothoulakis,et al.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis , 1997, Gut.

[103]  M. Delmée,et al.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection , 1994, Infection and immunity.

[104]  M. Delmée,et al.  Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). , 2014, The Lancet. Infectious diseases.

[105]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control & Hospital Epidemiology.

[106]  Carol A. Keohane,et al.  Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. , 2013, JAMA internal medicine.

[107]  M. Mellow,et al.  Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients , 2014, The American Journal of Gastroenterology.

[108]  L. Peterson,et al.  Treatment of Asymptomatic Clostridium difficile Carriers (Fecal Excretors) with Vancomycin or Metronidazole , 1992, Annals of Internal Medicine.

[109]  R. Fekety.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. , 1997, The American journal of gastroenterology.

[110]  Fernanda C. Lessa,et al.  Current Status of Clostridium difficile Infection Epidemiology , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[111]  D. Gerding,et al.  Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. , 2013, JAMA internal medicine.

[112]  E. Bouza,et al.  Consequences of Clostridium difficile infection: understanding the healthcare burden. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[113]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[114]  Les Dethlefsen,et al.  The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing , 2008, PLoS biology.

[115]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[116]  C. Donskey,et al.  Persistence of Skin Contamination and Environmental Shedding of Clostridium difficile during and after Treatment of C. difficile Infection , 2010, Infection Control & Hospital Epidemiology.

[117]  Michael B Gravenor,et al.  Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial , 2013, The Lancet.

[118]  Susanne Hempel,et al.  Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. , 2012, JAMA.

[119]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[120]  J. Rask-Madsen,et al.  BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS , 1989, The Lancet.

[121]  Y. Trnka,et al.  THERAPEUTIC IMPLICATIONS OF CLOSTRIDIUM DIFFICILE TOXIN DURING RELAPSE OF CHRONIC INFLAMMATORY BOWEL DISEASE , 1980, The Lancet.

[122]  C. Kelly,et al.  An epidemic of pseudomembranous colitis: importance of person to person spread. , 1987, Gut.

[123]  D. Gerding,et al.  Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization. , 2012, The Journal of infectious diseases.

[124]  R. Wenzel,et al.  Handwashing compliance by health care workers: The impact of introducing an accessible, alcohol-based hand antiseptic. , 2000, Archives of internal medicine.

[125]  L. Peterson,et al.  Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. , 1990, The American journal of medicine.

[126]  P. Gilligan,et al.  Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of Clostridium difficile-associated diseases , 1993, Journal of clinical microbiology.

[127]  J. Silva,et al.  Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. , 1989, The American journal of medicine.

[128]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[129]  C. Kelly,et al.  Underlying Disease Severity as a Major Risk Factor for Nosocomial Clostridium difficile Diarrhea , 2002, Infection Control & Hospital Epidemiology.

[130]  M. Rupnik,et al.  Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.